AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 28 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 23 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 8 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 3 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Net sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net sales combined with diligent cost containment...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Executive appointments to strengthen financial and legal leadership during the transformation of the company St. Gallen, Switzerland, 02 February 2022...

First orally administered therapy for the treatment of the two main types of ANCA-associated vasculitis approved in Europe First launches expected in H1 2022 St. Gallen, Switzerland, 19 January...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 18 January 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Phase-IIIb trial demonstrates statistically significant outcome on the primary endpoint Largest study to date showing benefit of Veltassa® (patiromer)...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Abbreviated New Drug Application (ANDA) disputes regarding Injectafer® (ferric carboxymaltose) have now been settled St. Gallen, Switzerland, and...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Focus on expansion in nephrology, and to maximize opportunities on the iron portfolio Vifor Pharma to divest non-core assets on finished drug product...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR St. Gallen, Switzerland, 13 December 2021 – Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR St. Gallen, Switzerland, and Uniondale, NY,– 10 December 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Hervé Gisserot will join Vifor Pharma as Chief Commercial Officer on 17 January 2022 Responsibilities of Sales, Marketing and Market Access to be...

Vamifeport (VIT-2763) is the first oral ferroportin inhibitor investigated for treatment of diseases with ineffective production of red blood cells and iron overload such as sickle cell disease (SCD)

Ad hoc announcement pursuant to Art. 53 LR St. Gallen, Switzerland, 02 December 2021 – Due to current market speculations, Vifor Pharma Group states the following: Vifor Pharma Group...

Ad hoc announcement pursuant to Art. 53 LR Colin Bond to retire as Chief Financial Officer of Vifor Pharma Group Succession recruitment ongoing St. Gallen, Switzerland, 30 November 2021 - Vifor...

Iron Deficiency Day unites a strong international coalition dedicated to raising international awareness on the serious health impact of iron deficiency and iron deficiency anemia1 Patient access...

Ad hoc announcement pursuant to Art. 53 LR Sanifit Therapeutics and Inositec AG, both clinical stage biopharmaceutical companies, are developing first-in-class treatments for progressive vascular...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of first orally administered therapy for the treatment of ANCA-associated...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Phase-III trial did not demonstrate a statistically significant difference from placebo on the primary endpoint of estimated Glomerular Filtration Rate...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Executive committee members Lee Heeson and Gregory Oakes to leave the company for personal reasons Succession planning ongoing St. Gallen, Switzerland,...